XENEXenon Pharmaceuticals Inc.vs its industry peers
A metric-by-metric comparison of Xenon Pharmaceuticals Inc. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XENE본 종목 | $5.6B#5 | — | 4.5x#1 | 740.8x#4 | — | -47.6%#4 | -4974.3%#4 | -27.8%#2 | -32.5%#2 | — | 56.4%#3 | — |
| RVMD | $41.8B#2 | — | 16.0x#4 | — | — | -88.5%#5 | — | -43.4%#4 | — | — | 345.4%#2 | — |
| MRNA | $63.3B#1 | — | 9.4x#3 | 32.6x#2 | -39.9%#3 | 20.8%#2 | -158.1%#2 | -41.7%#3 | -54.6%#3 | — | 534.4%#1 | — |
| INSM | $26.9B#3 | — | 35.5x#5 | 44.4x#3 | 66.7%#1 | -39.7%#3 | -205.6%#3 | -168.6%#5 | -163.0%#4 | 3#1 | -14.9%#5 | — |
| INCY | $25.2B#4 | 17.8x#1 | 4.5x#2 | 4.9x#1 | 21.2%#2 | 3846.9%#1 | 29.5%#1 | 22.9%#1 | 49.0%#1 | — | 48.8%#4 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice